### M8011

# **Evaluating Complex Emulsion and Liposome Morphology in Propofol Drug Products with High Resolution Cryogenic Electron Microscopy**

Yong Wu<sup>1</sup>, Peter Petrochenko<sup>2</sup>, Jikun Liu<sup>3</sup>, Soumyarwit Manna<sup>2</sup>, Bonhye Koo<sup>2</sup>, Ja Hye Myung<sup>2</sup>, Lynn Chen<sup>2</sup>, Stephanie Choi<sup>2</sup>, Darby Kozak<sup>2</sup>, Jiwen Zheng<sup>1</sup>

<sup>1.</sup> Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, <sup>2.</sup> Division of Therapeutic Performance, Office of Research Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, <sup>3.</sup> Division of Product Science, Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD 20993


CONTACT INFORMATION: yong.wu@fda.hhs.gov

### PURPOSE

Propofol (2,6-diisopropylphenol) is a commonly used intravenous drug for the induction and maintenance of general anesthesia or sedation. Due to the insolubility of propofol in water, it is formulated as an oil-in-water emulsion stabilized by egg lecithin phospholipids. Addition of excess phospholipids will, in practice, give rise to the formation of both emulsion and liposomes, i.e. vesicular structures formed of a bilayer of phospholipids, in the formulation. However, the presence, amount, morphology and potential impact of these structures is relatively unknown. In this study, we investigate the use of high resolution Cryo transmission electron microscopy (cryo-TEM) to measure the presence, content and structures of liposomes formed in four propofol injectable emulsion products. Cryo-TEM can be used to quantify the size distribution and composition of complex coexisting structures which can be used to support drug product quality and equivalence assessment.

### METHODS

- Cryo transmission electron microscopy (cryo-TEM) was performed using a Jeol 1400 TEM/STEM equipped with a Leica EM GP grid plunge freezer.
- Dynamic light scattering (DLS) and zeta potential were performed using a Malvern Zetasizer. Three separate dilutions were run with at least 5 measurements per sample. Samples were diluted 1000X with DI water and borate buffer for DLS and zeta potential, respectively.
- Capillary electrophoresis (CE) was performed on an Agilent 7100 Capillary Electrophoresis system. For injection samples, a volume of 1  $\mu$ L propofol sample is mixed with 100  $\mu$ L sodium tetraborate buffer (Agilent; 20 mM, pH 9.3) and 5 µL dimethyl sulfoxide (DMSO) solution (1%, v/v in water; electroosmotic flow marker).







**FDA U.S. FOOD & DRUG** ADMINISTRATION

### RESULTS

### **Cryo-TEM micrograph of propofol samples**






Cryo-TEM enables discrimination and measurement of nano and micro-structures within complex formulations such as the presence of both emulsion droplets and liposomes in propofol emulsion products from different manufacturers.


Emulsion



Liposome





Aggregate



Liposome component of aggregate Emulsion component of aggregate


Particle size distribution of emulsion, liposome and aggregate







The population and size distribution of by-product structures, liposome and emulsion/liposome aggregate, varied among products.







### **Proportion of emulsion, liposome and aggregate**









## **RESULTS (CONT'D)**





measurements



## CONCLUSIONS

- Cryo-TEM results demonstrate that all propofol products contain a mixture of oil-inwater emulsions, liposomes and emulsion/liposome aggregates.
- All products contain similar proportion and particle size distribution of the emulsions (the main carrier of the drug substance) whereas slight differences of the by-product structures (liposomes and aggregates) are observed.
- Cryo-TEM is a powerful characterization technique for analyzing complex drug products comprising coexisting morphologies.

### ACKNOWLEDGEMENTS

The authors would like to acknowledge the FDA Advanced Characterization Facility (ACF) and CDRH/OSEL/DBCMS for instrument use. The author would also like to thank Dr. Indira Hewlett for allowing us to access CE and provide technical support/valuable discussion. Dr. Yong Wu was supported in part by an appointment to the Oak Ridge Institute for Science and Education (ORISE) Research Participation Program at CDRH administered by the ORISE through an agreement between the U.S. Department of Energy and CDRH.

### DISCLAIMER

The views expressed in this poster do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.



• The capillary electrophoresis separation shows different retention time, indicating potential differences in particle size and/or surface charge populations in each of the products. Broadened peak indicates heterogeneous particle size distribution.